Overview

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Status:
RECRUITING

Trial end date:
2031-02-19

Target enrollment:

Participant gender:

Summary

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

Phase:

PHASE3

Details

Lead Sponsor:

AstraZeneca

Collaborators:

Daiichi Sankyo Co., Ltd.
European Network for Gynaecological Oncological Trial groups(ENGOT)
Gynecologic Oncology Group (GOG) Foundation Inc.

Treatments:

Carboplatin
Docetaxel
Paclitaxel
pembrolizumab
trastuzumab deruxtecan